Skip to main content
SeouLinBioscienceCO.,LTD. logo

SeouLinBioscienceCO.,LTD. — Investor Relations & Filings

Ticker · 038070 ISIN · KR7038070009 KO Professional, scientific and technical activities
Open in API
Filings indexed 209 across all filing types
Latest filing 2024-03-28 Declaration of Voting R…
Country KR South Korea
Listing KO 038070

About SeouLinBioscienceCO.,LTD.

SeouLin Bioscience is a total solutions provider for the life sciences and healthcare sectors, specializing in bio-research and production. Established in 1984, the company supplies a comprehensive range of research reagents, laboratory equipment, and materials. It also develops and manufactures specialized products, including Hypochlorous Acid (HOCl) sterilization water generators, DNA chip scanners, and diagnostic DNA kits. The company's research and development activities focus on creating novel diagnostic solutions, such as field kits for detecting marine viruses and pathogens related to food safety. SeouLin Bioscience aims to deliver integrated solutions that support scientific discovery and bioproduction processes.

Recent filings

Filing Released Lang Actions
[기재정정]정기주주총회결과
Declaration of Voting Results & Voting Rights Announcements Classification · 1% confidence The document is an official filing titled '정기주주총회결과' (Annual General Meeting Results) for Seorin Bio. It details the outcomes of the shareholder meeting, including the approval of financial statements, dividend resolutions, and the election of directors. This falls directly under the definition of a Declaration of Voting Results & Voting Rights Announcement (DVA), as it reports the official results of shareholder votes at an AGM.
2024-03-28 Korean
전환가액의조정
Capital/Financing Update Classification · 1% confidence The document is a formal regulatory filing from Seorin Bio regarding the adjustment of the conversion price of convertible bonds due to stock dividends. This type of disclosure, which details changes to capital structure and financial instruments, falls under the category of 'Capital/Financing Update' (CAP) as it directly relates to the company's financing activities and the terms of its outstanding debt instruments.
2024-03-28 Korean
[기재정정]주주총회소집공고
AGM Information Classification · 1% confidence The document is a 'Correction Report' (정정신고) regarding a 'Notice of Convocation of General Meeting of Shareholders' (주주총회소집공고). It contains detailed financial statements (balance sheets, income statements, cash flow statements) as part of the management reference materials for the upcoming shareholder meeting. Since the primary purpose of the document is to provide information for the Annual General Meeting (AGM), including the agenda and financial disclosures for shareholder approval, it is classified as AGM-R.
2024-03-21 Korean
감사보고서제출
Audit Report / Information Classification · 1% confidence The document is a formal 'Audit Report Submission' (감사보고서 제출) filed by Seorin Bio. It contains the auditor's opinion (적정/Unqualified), financial statements (consolidated and separate), and details regarding the audit process. While it provides financial data, it is a specific regulatory filing required by the KRX (Korea Exchange) to announce the receipt and submission of the audit report, rather than the full 10-K annual report document itself. Therefore, it is classified as an Audit Report/Information document. FY 2023
2024-03-20 Korean
사업보고서 (2023.12)
Annual Report Classification · 1% confidence The document is a 'Consolidated Audit Report' (연결감사보고서) for Seorin Bioscience for the fiscal year ending December 31, 2023. It includes the independent auditor's report, consolidated financial statements (balance sheet, income statement, statement of changes in equity, cash flow statement), and detailed notes. This document constitutes the full annual financial reporting package, which falls under the 'Annual Report' (10-K) category in the provided schema, as it contains the comprehensive financial performance and audit results for the full fiscal year. FY 2023
2024-03-20 Korean
매출액또는손익구조30%(대규모법인은15%)이상변동
Earnings Release Classification · 1% confidence The document is a regulatory filing from the Korean stock exchange (KRX) regarding a significant change in financial performance (revenue or profit structure change of 30% or more). This is a standard disclosure requirement for listed companies in Korea to report material financial fluctuations. Since it is a specific regulatory disclosure of financial results rather than a full annual report, a conference call transcript, or a simple announcement of a report, it falls under the 'Regulatory Filings' category. FY 2023
2024-03-13 Korean

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.